Scienza e Tecnologia
Introducing BICO: The Global Leader in the Bio Convergence Revolution
In the last five years, BICO has seen exponential growth including expansion to 900+ employees over 11 subsidiaries, as well as sales and distribution in 65+ countries in over 2,000 laboratories. The launch of BICO draws a clear path for the future of the company by developing the future of health among three key business areas: Bioprinting, Biosciences and Bioautomation. By combining these different technologies, BICO will enable its customers and researchers to improve people's health and lives for the better. CELLINK Bioprinting will continue to prosper under the BICO umbrella as the strong industry leader in 3D bioprinting and with its broad portfolio of consumables e.g., bioinks and tissue engineering products.
" ", said Erik Gatenholm, CEO and President BICO. "A "
The company will be focused around five central areas, including the enabling of safer and accessible organ transplants, utilization of cultivated tissue from human cells to eliminate unnecessary animal testing, faster development of more affordable medicines, more personalized medicines, as well as faster and less expensive diagnostics to fight infectious diseases.
" ", said Dr. Robert Langer , professor at the Massachusetts Institute of Technology , co-founder of Moderna and member of the BICO Scientific Advisory Board. " "
The subsidiaries that are a part of BICO will keep their names and operate as individual companies. The company's ticker has been updated from CLNK to BICO. There have been no additional changes to the company's financial instruments.
BICO press kit available in press room section on www.bico.com.
Phone (Sweden): +46 70 830 0890
Email:
Riley Munks, PR Manager (650) 863-6699
Alyssa D'Orazio, PR Manager (617) 634-9601
Email:
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group's products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on the Nasdaq the Stockholm under BICO. www.bico.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bico-group-ab/r/introducing-bico--the-global-leader-in-the-bio-convergence-revolution,c3399026
The following files are available for download: